A Randomized, Double-blind, Active Control, Parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of Fimasartan
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 351 participants.
Also called NCT02620306
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 351 participants
- Registry
-
NCT02620306
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT02620306. Randomized; quadruple masking; primary purpose treatment. Start 2016-02-11 (actual); primary completion 2019-12-23 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Randomized, Double-blind, Active Control, Parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of Fimasartan
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Fimsartan 60mg~120mg
- Intervention (Drug)
- Fimsartan 60mg~120mg
- Intervention (Drug)
- Losartan 50mg~100mg
- Intervention (Drug)
- Losartan 50mg~100mg
- Lead sponsor
- Boryung Pharmaceutical Co., Ltd
Record details
- Record id
cardio:ct-nct02620306- Content hash
58b16b04b9773a8a8c9344a7015205dac779535581f7135f14650ec4b4348efb